Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-357-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.99 million
Profitability
Miscellaneous
Employees167
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) posted its quarterly earnings data on Friday, May, 10th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.03. The biopharmaceutical company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.45 million. Ocular Therapeutix had a negative return on equity of 165.85% and a negative net margin of 2,956.91%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
6 Wall Street analysts have issued twelve-month target prices for Ocular Therapeutix's stock. Their forecasts range from $3.00 to $24.00. On average, they anticipate Ocular Therapeutix's stock price to reach $9.6667 in the next twelve months. This suggests a possible upside of 118.7% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.
What is the consensus analysts' recommendation for Ocular Therapeutix?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.
What are Wall Street analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/16/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $24 on 4Q18/2018 earnings results. Our top focus for 2019 will be measuring the DEXTENZA launch (sampling expected to begin in May, followed by a formal launch by July)." (3/7/2019)
Has Ocular Therapeutix been receiving favorable news coverage?
Media headlines about OCUL stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ocular Therapeutix earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Ocular Therapeutix.
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Odonate Therapeutics (ODT), Mallinckrodt (MNK), Vanda Pharmaceuticals (VNDA), Aptorum Group (APM), Kura Oncology (KURA), Intra-Cellular Therapies (ITCI), DiaMedica Therapeutics (DMCAF), Arvinas (ARVN), Stemline Therapeutics (STML), CannTrust (CTST), Zymeworks (ZYME), Myovant Sciences (MYOV), Organogenesis (ORGO), ZEALAND PHARMA/S (ZEAL) and Cytokinetics (CYTK).
What other stocks do shareholders of Ocular Therapeutix own?
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
- Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 62)
Who are Ocular Therapeutix's major shareholders?
Ocular Therapeutix's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (4.30%), Deltec Asset Management LLC (1.93%), Jennison Associates LLC (0.59%), Mercer Global Advisors Inc. ADV (0.21%), Mercer Global Advisors Inc. ADV (0.21%) and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.05%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein and Richard L Md Lindstrom. View Institutional Ownership Trends for Ocular Therapeutix.
Which major investors are selling Ocular Therapeutix stock?
Which major investors are buying Ocular Therapeutix stock?
OCUL stock was acquired by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Mercer Global Advisors Inc. ADV, Mercer Global Advisors Inc. ADV, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA and BNP Paribas Arbitrage SA. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein and Richard L Md Lindstrom. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $4.42.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $189.35 million and generates $1.99 million in revenue each year. The biopharmaceutical company earns $-59,980,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe.View Additional Information About Ocular Therapeutix.
What is Ocular Therapeutix's official website?
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
